New Medicare GLP-1 Program: How to Check Your Eligibility
The Centers for Medicare and Medicaid Services (CMS) has initiated a pilot program termed the Medicare GLP-1 Bridge, designed to offer certain Medicare beneficiaries access to GLP-1 weight loss medications at a reduced copay of per month. Launched on July 1, this program aims to address the growing concern of obesity and its related health issues among older adults and other qualifying individuals under Medicare.
Typically known for providing healthcare coverage primarily to older adults, Medicare’s eligibility criteria for this program are more selective. The GLP-1 Bridge is part of Medicare Part D, which covers prescription medications but does not extend to individuals who already have coverage for GLP-1s. As a result, participants diagnosed with diabetes, who may need these medications, will not qualify under this program but may seek alternatives through their existing drug plans.
As a pilot initiative, the GLP-1 Bridge is scheduled to run until the end of 2027, with specific eligibility requirements. Candidates must have Medicare drug coverage and not currently be enrolled in a plan covering GLP-1s. Additionally, applicants must meet at least one of the following criteria: possess a body mass index (BMI) of 35 or greater; have a BMI between 30 and 35 accompanied by any of several specified health conditions, including heart failure or hypertension; or have a BMI between 27 and 30 along with specific medical concerns such as prediabetes.
Recent analyses by the Kaiser Family Foundation (KFF) estimate that as many as 3.8 million Medicare beneficiaries could be eligible for the GLP-1 Bridge program. The Medicare leadership anticipates starting participation with a few million beneficiaries.
Individuals who qualify will be able to receive medications such as Foundayo, Wegovy, or Zepbound, although the copay will not contribute towards their annual deductible, as it operates outside the standard Medicare framework.
To enroll in the program, potential participants must first consult with their healthcare providers. Providers will need to submit a prescription along with a prior authorization form to Medicare. Once approved, beneficiaries will receive a confirmation letter outlining the coverage specifics, which will remain valid until the program’s conclusion in 2027.
For further details regarding eligibility and the enrollment process, individuals can refer to the official Medicare website or contact Medicare directly at 1-800-MEDICARE. This new initiative reflects a growing recognition of the need to combat obesity through accessible medication solutions within the Medicare structure.
